136 related articles for article (PubMed ID: 7954466)
21. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
22. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
23. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
24. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
26. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
Frühauf S; Zeller WJ
Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
[TBL] [Abstract][Full Text] [Related]
27. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
28. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Nicolson MC; Orr RM; O'Neill CF; Harrap KR
Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
30. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
Fram RJ; Woda BA; Wilson JM; Robichaud N
Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
[TBL] [Abstract][Full Text] [Related]
31. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
32. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
33. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
34. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
35. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells.
Jekunen AP; Hom DK; Alcaraz JE; Eastman A; Howell SB
Cancer Res; 1994 May; 54(10):2680-7. PubMed ID: 8168097
[TBL] [Abstract][Full Text] [Related]
36. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
37. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
Parker RJ; Eastman A; Bostick-Bruton F; Reed E
J Clin Invest; 1991 Mar; 87(3):772-7. PubMed ID: 1999494
[TBL] [Abstract][Full Text] [Related]
38. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Andrews PA; Velury S; Mann SC; Howell SB
Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
[TBL] [Abstract][Full Text] [Related]
39. Cell biological markers of drug resistance in ovarian carcinoma.
van der Zee AG; Hollema HH; de Bruijn HW; Willemse PH; Boonstra H; Mulder NH; Aalders JG; de Vries EG
Gynecol Oncol; 1995 Aug; 58(2):165-78. PubMed ID: 7622101
[TBL] [Abstract][Full Text] [Related]
40. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
Lau DH; Ross KL; Sikic BI
Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]